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To establish an efficient, reliable and easy to apply risk assessment tool to select families with breast and/or ovarian cancer patients for
BRCA mutation testing, using available probability models. In a retrospective study of 263 families with breast and/or ovarian cancer
patients, the utility of the Frank (Myriad), Gilpin (family history assessment tool) and Evans (Manchester) model was analysed, to
select 49 BRCA mutation-positive families. For various cutoff levels and combinations, the sensitivity and specificity were calculated
and compared. The best combinations were subsequently validated in additional sets of families. Comparable sensitivity and specificity
were obtained with the Gilpin and Evans models. They appeared to be complementary to the Frank model. To obtain an optimal
sensitivity, five ‘additional criteria’ were introduced that are specific for the selection of small or uninformative families. The optimal
selection is made by the combination ‘Frank X16% or Evans2 X12 or one of five additional criteria’. The efficiency of the selection of
families for mutation testing of BRCA1 and BRCA2 can be optimised by using a combination of available easy to apply risk assessment
models.
British Journal of Cancer (2006) 95, 757–762. doi:10.1038/sj.bjc.6603306 www.bjcancer.com
Published online 15 August 2006
& 2006 Cancer Research UK
Keywords: breast cancer; ovarian cancer; BRCA1; BRCA2; mutation; probability model
                                               
Identification of families at high risk of hereditary breast and/or
ovarian cancer contributes to the prevention and early detection of
breast and ovarian malignancies. Therefore, genetic testing is
offered to women with an increased risk of hereditary breast or
ovarian cancer based on familial clustering of breast and/or
ovarian cancer, particularly in case of early onset or if breast
cancer occurs in a male. Selection criteria to test for BRCA
mutations vary. Because BRCA testing is laborious and expensive,
as well as associated with medical, psychological and social
consequences for the patient, careful patient selection is required
before testing. To obtain optimal ascertainment, many risk
assessment models and prior probability models have been
developed and evaluated (de la Hoya et al, 2003; Domchek et al,
2003). Four such models, the Claus, Gilpin, Frank and Evans model
(Claus et al, 1998; Gilpin et al, 2000; Frank et al, 2002; Evans et al,
2004) are empirically derived scoring systems, easy to apply in
daily practice with the use of a pencil and a paper and easy to
understand for both counsellor and patient.
With the Claus tables the probability of developing breast cancer
can be determined, but not the likelihood of detecting a BRCA
mutation (as in prior probability models). These tables are based
on series of unselected women with breast cancer. As this model
does not account for breast cancer in more than two family
members, the presence of ovarian cancer, male breast cancer or
bilateral breast cancer, it underestimates the cancer risk in many
families and cannot be used solely as a prediction model in the
clinic.
The Frank model, developed by Myriad Genetics, is an empirical
model correlating the prevalence of BRCA mutations with personal
and family history of breast and ovarian cancer and is based on
thousands of women tested for BRCA1 and BRCA2 in a diagnostic
setting. The outline of this scoring system is shown in Table 1.
Both previous models do not account for the presence of bilateral
breast cancer, although this is a predictor for the presence of BRCA
mutations (Ligtenberg et al, 1999). Gilpin et al (2000) defines a
family history assessment tool (FHAT) that does include bilaterality
and ovarian cancer as well as other suggested variables that are
prevalent in BRCA families, like prostate cancer and colon cancer
diagnosed before age 50 (Bermejo and Hemminki, 2004; Table 1).
Like Gilpin et al (2000), Evans et al (2005) developed a simple
and quick scoring system (Manchester scoring system). This
model was developed using empirical data from families tested for
BRCA1 or BRCA2 mutations. The scoring mainly depends on the
type of cancer and age at diagnosis and is different for the
prediction of BRCA1 and BRCA2 mutation-positive families
(Evans1 and Evans2 scores; Table 1). The 10 point cutoff level
identifies a 410% likelihood to find in particular BRCA2, but also
BRCA1 mutations.
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sAlthough the number of BRCA analyses increased dramatically
over the last 10 years, the number of mutation-positive results did
not follow this increase. To reduce the number of negative test
results, we correlated the outcome of the aforementioned simple,
quick and easy to apply prediction models on families with breast
and/or ovarian cancer previously screened for BRCA mutations
with the mutation status. The sensitivity of the selection criteria
was subsequently improved by changing cutoff levels, combining
models, and by adding five so-called ‘additional selection criteria’.
This new combination of selection criteria for BRCA testing was
validated on two other sets of BRCA mutation tested families from
two different clinics.
PATIENTS AND METHODS
Study population
The cohort studied consists of 263 families with breast and/or
ovarian cancer patients that were tested for BRCA mutations, after
thorough genetic counselling, between 1999 and 2001, at the
Radboud University Medical Centre Nijmegen. Information about
the family history was reported to a clinical geneticist by the index
patient, that is, the affected family member who was considered to
have the highest prior probability of carrying a BRCA mutation
and who was the first to be tested in the family. The pedigrees were
anonymised before analysis and cancer diagnoses were verified
wherever possible. In the period 1999–2001, the selection of
families for DNA testing was mainly based on expert opinion of
clinical geneticists, using the Claus tables (selection when breast
cancer risk was three times the population risk: X30%). In 2001
the Gilpin and Frank models were added to the Claus tables
and genetic testing was offered if one of these scores was X10. In
this study, we used the Myriad mutation prevalence tables of
1 August 2002 (Frank model; http://www.myriadtests.com/provider/
mutprev.htm).
Validation of the thus defined combination of selection criteria
and cutoff levels was performed in two additional family sets. One
consisted of 197 breast/ovarian cancer families counselled and
tested in 2002 at the Radboud University Medical Centre Nijmegen,
of which 34 families were tested BRCA mutation-positive. The other
set consisted of 101 BRCA mutation-positive families counselled
and tested at the University Medical Centre Groningen.
Mutation detection in BRCA1 and BRCA2
The mutations were identified by analysis of the entire coding
sequences and intron/exon boundaries of the genes using a
combination of techniques: protein truncation test of BRCA1 and
BRCA2 exon 11; denaturing gradient gel electrophoresis of the
other coding exons including the 50 and 30 regions of the exons 11
(Hout van der et al, 1999); and multiplex ligation-dependent probe
amplification to detect exon deletions or duplications (Schouten
et al, 2002; Hogervorst et al, 2003). All positive tests were
confirmed by direct sequencing. Unclassified variants were not
included in this study.
Scoring systems
The Claus, Frank, Gilpin and Evans scores were determined
following description in the published papers. The Evans scores
were calculated up till third degree family members.
Data analysis
The significance of the difference between the median prediction
scores determined with the different models and correlated with
Table 1 Outlines of the Frank, Gilpin and Evans scoring systems for the BRCA mutation prediction
Prediction model Outlines
Frank K Prevalence of mutations in BRCA1 and BRCA2 correlated with personal and family history of cancer in thousands of women tested for
BRCA1 and BRCA2 in a diagnostic setting.
K Family history includes at least one first- or second-degree relative and excludes proband
Characteristics scored for
K Age of onset breast cancer (o or X50 years)
K Ovarian cancer at any age
K Combined breast and ovarian cancer within one patient
Gilpin K Weighting system in which points are given to certain characteristics of cancers in affected individuals. The points is predictive for the
mutation status
K Family history includes all first, second and third degree family members
Characteristics scored for
K Age of onset breast cancer (20–29; 30–39; 40–49 years)
K Age of onset ovarian cancer (o40; 40–60; 460 years)
K Age of onset prostate cancer (o or X50 years)
K Age of onset colon cancer (o or X50 years)
K Bilateral/multifocal breast tumours
K Combined breast and ovarian cancer within one patient
K Male breast cancer
Evans (BRCA1 and BRCA2
scored separately)
K Separate scoring system for BRCA1 and BRCA2 mutation prediction
K Weighting system in which points are given to certain characteristics of cancers in affected individuals. The points is predictive for the
mutation status
K Family history includes all first, second and third degree family members
K Each breast cancer if bilateral/multifocal is counted separately
Characteristics scored for
K Age of onset breast cancer (o30; 30–39; 40–49; 50–59; 459 years)
K Age of onset ovarian cancer (o or X60 years)
K Age of onset prostate cancer (o or X60 years) (for BRCA2 only)
K Pancreatic cancer at any age (for BRCA2 only)
K Male breast cancer (for BRCA2 only)
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sthe mutation status of these families was calculated with a Mann–
Whitney U-test. We evaluated the different prediction scoring
systems and different cutoff levels by calculating the sensitivity,
specificity and predictive values. Sensitivity of the selection criteria
is the proportion of BRCA mutation carriers who fulfil the
selection criteria (higher than or equal to the cutoff level).
Specificity is the proportion of noncarriers who do not fulfil the
selection criteria (below the cutoff level). The positive predictive
value is the proportion of individuals who fulfil the selection
criteria and who carry a BRCA mutation. The negative predictive
value is the proportion of individuals who do not fulfil the
selection criteria and who do not carry a BRCA mutation. We
calculated the probability of a BRCA mutation for each woman.
Subsequently, these probabilities were used to construct a receiver
operating characteristic (ROC) curve in order to visualise the
predictive power of the variables. The area under the ROC curve (C
statistic) quantifies this predictive power.
RESULTS
To determine the BRCA mutation prediction capability of the
Claus, Frank, Gilpin, Evans1 and Evans2 models, the prediction
scores were determined for 263 families with breast and/or ovarian
cancer patients and compared to the mutation status of these
families. For both the BRCA-positive and -negative families, the
median prediction scores for the five models were calculated. For
the Claus model, no significant difference in this score was
observed between BRCA-positive and -negative families
(P¼0.168). The Frank, Gilpin, Evans1 and Evans2 model showed
a significant difference in the prediction scores (Po0.0001) and
were studied in more detail.
The prediction scores were also determined for BRCA1 and
BRCA2 mutation-positive families separately (Figure 1). In all
models, the prediction score for the BRCA1 families was
significantly better than for the BRCA2 families (P-value varied
from 0.008 for the Gilpin and Evans1 models to 0.047 for the Frank
model). For the Gilpin model, the difference in the prediction
scores between BRCA2 families and noncarriers was not significant
(P¼0.113). The Evans2 gave the best difference between BRCA2
families and noncarriers (P¼0.012). All models did distinguish
significantly the BRCA1 families from the noncarriers (Po0.0001).
In order to visualise the predictive power of each model, ROC
curves were generated for all models and the areas under the
curves (C statistic) were determined. The Evans1 model out-
performed all other models for the prediction of BRCA1 mutation-
positive families. The Evans2 model performed best for the
prediction of BRCA2 mutation-positive families. For all models we
assessed the sensitivity for BRCA1 mutation-positive families and
BRCA2 mutation-positive families for the advised cutoff levels
(X10 for all models). Thus, the Gilpin model scored best
(sensitivity BRCA1: 100%; sensitivity BRCA2: 88%, two families
missed). The Evans1 and Evans2 model scored disappointing for
BRCA2 families. Only 50% of all BRCA2 families were selected. For
BRCA1 families, the Evans1 and Evans2 selection scored much
better and only one family was missed. With the Frank model, four
BRCA1 mutation-positive families were missed (sensitivity of 88%)
and four BRCA2 mutation-positive families (sensitivity of 75%).
To improve the efficiency of selection for BRCA mutation
testing, the sensitivity and specificity were calculated for various
cutoff levels in all models (Table 2 and Supplementary data Table
1). As expected, the sensitivity decreased and the specificity
increased when higher cutoff levels were used. However, no clear
optimal combination of sensitivity and specificity could be
reached. Scatter plots revealed that the models complement each
other in several families (data not shown). Therefore, combina-
tions of different cutoff levels of the two models were tested
(Table 2 and Supplementary data Table 2).
Overall, the combination of two prediction scores had a higher
sensitivity than each individual model although the specificity
decreased. ‘Frank X16 or Evans2 X12’ showed the to be the best
combination with respect to highest sensitivity and specificity (96
and 47%, respectively; Table 2). Only two mutation-positive
families were missed. These two families were BRCA2 mutation-
positive families. In one of these families, a mother and daughter
had developed breast cancer at age 56 and 26, respectively (Frank:
7.8%; Gilpin: 6; Evans1: 8; Evans2: 7). In the other family, two
sisters had breast cancer at the ages 47 and 52 and one brother
developed pancreatic cancer (Frank: 8.3%; Gilpin: 8; Evans2 (and
1): 5). Both families had very few female relatives. The combina-
tion of ‘Frank X16 or Gilpin X16’ had an almost equal sensitivity
and specificity of 94 and 40%, respectively (Table 2).
To include such BRCA mutation-positive cancer families, five
‘additional criteria’ were introduced that are focussed on
individual features of one affected person in a family at risk
(Table 3). These criteria include all relatives from the index patient
up till the third degree. Sensitivity, specificity and predictive values
were calculated for all models and model combinations in
combination with these ‘additional criteria’ (Table 2 and
Supplementary data Table 3). To obtain an optimal sensitivity,
we also varied the cutoff levels.
An optimal combination of sensitivity and specificity was
obtained with the combination ‘Frank X16 or Evans2 (or 1)
X12 or one of the additional criteria’. However, this combination
missed the same BRCA2 mutation-positive family (the two sisters
with breast cancer at the ages 47 and 52 and one brother with
pancreatic cancer) as none of the ‘additional criteria’ were fulfilled.
To obtain 100% sensitivity, the cutoff levels should be lowered
such, that there is hardly any specificity gained relative to the
initial selection based on expert opinion of clinical geneticists.
The specificity and positive predictive value were best for the
combination ‘Frank X16 or Evans1 (or 2) X12 or one of the
additional criteria’. With this selection combination, 22% less
families would have been tested for BRCA mutations than without
these criteria. With the selection combination ‘Frank X16 or
Gilpin X16 or one of the additional criteria’, this profit would have
been 18%.
Validation
The selection combinations, ‘Frank X16 or Gilpin X16 or one of
the additional criteria’ and ‘Frank X16 or Evans1 (or 2) X12 or
one of the additional criteria’, were validated in a cohort of 197
breast/ovarian cancer families tested in 2002. With the combina-
tion ‘Frank X16 or Gilpin X16 or one of the additional criteria’
only one BRCA2 family was missed. The same BRCA2 family was
also missed with the combination ‘Frank X16 or Evans1 X12 or
one of the additional criteria’. The combination ‘Frank X16 or
Evans2 X12 or one of the additional criteria’ missed besides this
BRCA2 family also one BRCA1 family. The specificity for these
combinations varied between 18 and 21% and is less than that for
the test group of 263 individuals. This difference may be due to a
difference in selection stringency of both groups. The families that
have been tested for BRCA mutations in 2002 scored higher
median selection scores for all models than the families that have
been tested between 1999 and 2001. The more stringent selection in
2002 thus explains the lower specificity in these analyses. Despite
of that, about 15–17% of all tested families would not have been
tested with these new selection combinations.
In the BRCA2-positive family that was missed with both the
selection combinations ‘Frank X16 or Gilpin X16 or one of
the additional criteria’ and ‘Frank X16 or Evans1 X12 or one
of the additional criteria’, the index case had developed breast
cancer at age 68. The mother and grandmother were both
diagnosed with breast cancer at ages 37 and 40, respectively, but
had died and could not be tested (Frank: 12%; Gilpin: 15; Evans1
Optimal selection for BRCA1 and BRCA2 mutation testing
D Bodmer et al
759
British Journal of Cancer (2006) 95(6), 757–762 & 2006 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s(and 2): 8). If the mother would have been chosen as the index, the
Frank and Gilpin scores would have been higher than 16 and thus
this family would have been included in the selection for BRCA
testing.
A second validation was performed for the combination ‘Frank
X16 or Gilpin X16 or one of the additional criteria’ in 101 BRCA-
positive families genetically tested at the University Medical Centre
Groningen (70 families with a BRCA1 mutation and 31 families
with a BRCA2 mutation). Only one BRCA2-positive family was
missed. In this family the index had developed breast cancer at age
61. Two sisters had also developed breast cancer but the ages were
not known and these variables could therefore not be added in the
scores. In this family, the lack of information is the cause of not
meeting the selection criteria. This family would also have been
missed with ‘Frank X16 or Evans2 (or 1) X12 or one of the
additional criteria’.
DISCUSSION
Efficacy of BRCA1 and BRCA2 mutation testing can be improved
by selection of families using both a combination of existing
probability models as well as higher cutoff levels than advised in
the previous publications. With a combination of easy to apply
probability models: ‘Frank X16 or Evans X12 or one of the
additional criteria’ a sensitivity of 98% was obtained with a
substantial reduction in the number of selected families for BRCA
testing as compared to the isolated use of one of these probability
models at cutoff level 10.
In our daily practice, the number of BRCA mutation analysis is
rapidly growing. However, the percentage of families with a
detected BRCA mutation is decreasing. This urged us to improve
the efficacy of the selection for mutation testing under the
precondition that no mutation carrying family is allowed to be
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Figure 1 Boxplot graphs from the Gilpin, Frank, Evans1 and Evans2 scores for the different families and their BRCA mutation status (BRCA1o rBRCA2
mutation negative; BRCA1 mutation-positive; BRCA2 mutation-positive). The line in the box indicates the median value of the data. The box itself contains the
middle 50% of the data. The ends of the vertical lines indicate the minimum and maximum data values. The points outside the ends are outliers.
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smissed. In our clinical genetic setting, five existing probability
models for the selection of BRCA mutation-positive families were
analysed: Claus, Frank, Gilpin, Evans1 and Evans2. The latter four
showed a good correlation with the mutation status and were
studied in more detail. Most risk assessment and prior probability
models are based on two or more affected family members and
thus form a general limitation for the selection of families that lack
family history information or families with only a few women.
Addition of so-called ‘additional criteria’ to these models increased
the sensitivity to almost 100%. These ‘additional criteria’ are
applicable for one affected individual. We applied these ‘additional
criteria’ for all affected members in a family up to the third degree
of the index person. In case no family member fulfils one of the
‘additional criteria’, the selection is dependent on the Frank, Gilpin
or Evans score.
The prevalence of BRCA1 and BRCA2 mutations among all
women diagnosed with an invasive breast cancer or ductal
carcinoma in situ is similar, and varies between 0.4–2.6% and
1.4–2.4%, respectively (Peto et al, 1999; Sanjose et al, 2003;
Claus et al, 2005). However, both in our settings as well as
in the literature, the families known to carry a BRCA1 mutation
outnumber those with a BRCA2 mutation by far (Newman et al,
1998; Syrjakoski et al, 2000; Claus et al, 2005). This may mean
that either BRCA2 mutations are less common or that a
considerable number of families actually carrying a BRCA2
mutation are missed, most likely because they are not recognised
by the current probability models. Consequently, a specific BRCA2
prediction model is needed. BRCA2 families differ less from
BRCA-negative mutation families than BRCA1 families do and may
therefore need stricter or different selection criteria. Additionally,
an explanation may be found in the fact that mutations in either
of the two genes are related to different life time risks for
nonbreast cancers such as ovarian cancer and prostate cancer
(Antoniou et al, 2003; Van Asperen et al, 2005). Evans et al
(2004) developed the so-called Evans2 model for the selection of
BRCA2 mutation-positive families. In our study, this model
was analysed for different combinations and cutoff levels.
Although ‘Gilpin X16’ scored most BRCA2 mutation-positive
families compared to the other models, the Evans2 model showed
the best accuracy for this type of families (area under the
ROC curve). However, in our study group, 50% of the BRCA2
families were missed in case the previously published cutoff level
of 10 was used.
The sensitivity for the selection of BRCA2 mutation-positive
families of the Evans2 model was strikingly lower in our study as
compared to the study by Evans et al. This difference may be
explained by difference in selection of the study population or by a
difference in carrier frequency between the British and the Dutch
population.
One family from the validation group with a BRCA2 mutation
was missed by the Frank model, because the index patient was
older than 50 years. The same family was also missed by the Gilpin
model as the family relation with affected relatives was too distant
(mother and grandmother from the affected index developed
breast cancer). When in this case the mother was chosen to be
index, the family would score X16 for both the Gilpin and Frank
Table 2 Sensitivity, specificity, positive and negative predictive values for different existing probability models seperately and in combination with each
other and in combination with the ‘additional criteria’ at different cut off levels in 263 families
Models and cut off levels Sensitivity Specificity
Positive predictive
value
Negative predictive
value
Frank X16 (41/49) 84% (110/214) 51% (41/145) 28% (110/118) 93%
Gilpin X16 (39/49) 80% (135/214) 63% (39/118) 33% (135/145) 93%
Evans1 X10 (40/49) 82% (119/214) 56% (40/135) 30% (119/128) 93%
Evans1 X12 (37/49) 76% (154/214) 72% (37/97) 38% (154/166) 93%
Evans2 X10 (40/49) 82% (116/214) 54% (40/138) 29% (116/125) 93%
Evans2 X12 (36/49) 73% (160/214) 75% (36/90) 40% (160/173) 92%
Frank X16 or Gilpin X16 (46/49) 94% (85/214) 40% (46/175) 26% (85/88) 97%
Frank X16 or Evans1 X10 (47/49) 96% (80/214) 37% (47/181) 26% (80/82) 98%
Frank X16 or Evans1 X12 (47/49) 96% (96/214) 45% (47/165) 28% (96/98) 98%
Frank X16 or Evans2 X10 (47/49) 96% (84/214) 39% (47/177) 27% (84/86) 98%
Frank X16 or Evans2 X12 (47/49) 96% (100/214) 47% (47/161) 29% (100/102) 98%
Evans1 X10 or Gilpin X16 (42/49) 86% (104/214) 49% (42/152) 28% (104/111) 94%
Evans1 X12 or Gilpin X16 (41/49) 84% (127/214) 59% (41/128) 32% (127/135) 94%
Evans2 X10 or Gilpin X16 (40/49) 82% (113/214) 53% (40/141) 28% (113/122) 93%
Evans2 X12 or Gilpin X16 (40/49) 82% (129/214) 60% (40/125)32% (129/138) 93%
Frank X16 or additional criteria (47/49) 96% (64/214) 30% (47/197) 24% (64/66) 97%
Gilpin X16 or additional criteria (44/49) 90% (77/214) 36% (44/181) 24% (77/82) 94%
Evans1 X10 or additional criteria (43/49) 88% (75/214) 35% (43/182) 24% (75/81) 93%
Evans1 X12 or additional criteria (42/49) 86% (92/214) 43% (42/164) 26% (92/99) 93%
Evans2 X10 or additional criteria (42/49) 86% (77/214) 36% (42/179) 23% (77/84) 92%
Evans2 X12 or additional criteria (41/49) 84% (92/214) 43% (41/163) 25% (92/100) 92%
Frank X16 or Gilpin X16 or additional criteria (48/49) 98% (48/214) 22% (48/214) 22% (48/49) 98%
Frank X16 or Evans1 X10 or additional criteria (48/49) 98% (49/214) 23% (48/213) 23% (49/50) 98%
Frank X16 or Evans1 X12 or additional criteria (48/49) 98% (57/214) 27% (48/205) 23% (57/58) 98%
Frank X16 or Evans2 X10 or additional criteria (48/49) 98% (48/214) 22% (48/214) 22% (48/49) 98%
Frank X16 or Evans2 X12 or additional criteria (48/49) 98% (57/214) 27% (48/205) 23% (57/58) 98%
The best combinations are marked by shading.
Table 3 Additional selection criteria specific for small BRCA mutation
positive families
1. Both breast and ovarian cancer (one or both diagnosed before age o60 year)
2. Male with breast cancer (at any age)
3. Bilateral breast cancer (diagnosed before age 45 years)
4. Ovarian cancer diagnosed before age 40 years
5. Breast cancer diagnosed before age 35 years
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that application of the selection models for BRCA mutation testing
preferably should start in a family member with either breast
cancer at the youngest age or with bilateral breast cancer or with
ovarian cancer. BRCA mutations can be missed when the person
with the highest probability to carry a mutation is not used as
index in applying the selection model.
During recent years many studies describing new risk assess-
ment models, prior probability models or comparisons of the
performance of some existing models have been published (De la
Hoya et al, 2003; Domchek et al, 2003; Marroni et al, 2004). A well-
known model is BRCAPRO. This program was validated retro-
spectively on families with and without a BRCA1 or BRCA2
mutation (Parmigiani et al, 1998; Berry et al, 2002). To use this
model a computer is needed. We did not include it in this study
aimed to determine optimal prediction using a simple, quick and
easy to apply probability model. In the present study we succeeded
to optimise existing easy applicable models by combining them
and adjusting the cutoff levels to a more specific and sensitive
selection.
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